With a one year PEG ratio of 0.21, Shockwave Medical Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.51% of US stocks.
Shockwave Medical Inc's stock had its IPO on March 7, 2019, making it an older stock than merely 2.75% of US equities in our set.
With a price/sales ratio of 46.71, Shockwave Medical Inc has a higher such ratio than 95.55% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Shockwave Medical Inc, a group of peers worth examining would be RAVN, GEOS, KN, CYRN, and VUZI.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020. Shockwave's management is scheduled for a live fireside chat on Wednesday, August 12, 2020, at 2:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at https://ir.shockwavemedical.com.About Shockwave Medical, Inc. Shockwave Medical is focused on developing and commercializing products intended to transform the way calcifi...
Shares of cardiovascular-health company Shockwave Medical (NASDAQ: SWAV) fell on Thursday after the Patent Trial and Appeal Board ruled that two of its patents are invalid. Previously, fellow healthcare-company Cardiovascular Systems (NASDAQ: CSII) challenged two of Shockwave Medical's patents and asked the U.S. Patent and Trademark Office to look into it. The '371 patent adds a couple of electrodes inside a balloon catheter to help break up calcification in blood vessels.